COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,254 Articles (22,733 medRxiv, 8,521 bioRxiv)

Most recent first Previous |  Page 669: Articles 6681-6690  | Next

Sphingosine kinases promote Ebola virus infection and can be targeted to inhibit filoviruses, coronaviruses, and arenaviruses using late endocytic trafficking to enter cells
Stewart, C. M., Bo, Y., Fu, K., Chan, M., Kozak, R., Apperley, K. Y.-P., Laroche, G., Beauchemin, A., Kobinger, G., Kobasa, D., Cote, M.
10.1101/2022.08.12.503750 — Posted: 2022-08-12
Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection
Wang, Z., Zhou, P., Muecksch, F., Cho, A., Tanfous, T. B., Canis, M., Witte, L., Johnson, B., Raspe, R., Schmidt, F., Bednarski, E., DaSilva, J., Ramos, V., Zong, S., Turroja, M., Millard, K. G., Yao, K., Shimeliovich, I., Dizon, J., Kaczynska, A., Jankovic, M., Gazumyan, A., Oliveira, T. Y., Caskey, M., Gaebler, C., Bieniasz, P. D., Hatziioannou, T., Nussenzweig, M. C.
10.1101/2022.08.11.503601 — Posted: 2022-08-12
SARS-CoV-2 specific plasma cells acquire the phenotype of long-lived plasma cells in the human bone marrow
Schulz, A. R., Hirseland, H., Diekmann, L.-M., Reinke, S., Hardt, S., Niedobitek, A., Mei, H. E.
10.1101/2022.08.11.503574 — Posted: 2022-08-12
Interfering with nucleotide excision by the coronavirus 3'-to-5' exoribonuclease
Chinthapatla, R., Sotoudegan, M. S., Anderson, T., Moustafa, I. M., Passow, K. T., Kennelly, S. A., Moorthy, R., Dulin, D., Feng, J. Y., Harki, D. A., Kirchdoerfer, R., Cameron, C. E., Arnold, J. J.
10.1101/2022.08.11.503614 — Posted: 2022-08-11
A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters
Chaturvedi, S., Beutler, N., Pablo, M., Vasen, G., Chen, X., Calia, G., Buie, L., Rodick, R., Smith, D., Rogers, T., Weinberger, L.
10.1101/2022.08.10.503534 — Posted: 2022-08-11
Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike protein
Yang, K., Wang, C., Kreutzberger, A. J. B., Ojha, R., Kuivanen, S., Couoh-Cardel, S., Muratcioglu, S., Eisen, T. J., White, K. I., Held, R. G., Subramanian, S., Marcus, K., Pfuetzner, R. A., Esquivies, L., Doyle, C. A., Kuriyan, J., Vapalahti, O., Balistreri, G., Kirchhausen, T., Brunger, A. T.
10.1101/2022.08.11.503553 — Posted: 2022-08-11
Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro
Hou, N., Shuai, L., Zhang, L., Xie, X., Tang, K., Zhu, Y., Yu, Y., Zhang, W., Tan, Q., Zhong, G., Wen, Z., Wang, C., He, X., Huo, H., Gao, H., Xu, Y., Xue, J., Peng, C., Zou, J., Schindewolf, C., Menachery, V., Su, W., Yuan, Y., Shen, Z., Zhang, R., Yuan, S., Yu, H., Shi, P.-Y., Bu, Z., Huang, J., Hu, Q.
10.1101/2022.08.10.503531 — Posted: 2022-08-11
Assessment of COVID-19 Effect on the Health of Families in South-West, Nigeria
olorunfemi, o.
10.1101/2022.08.10.22278638 — Posted: 2022-08-11
Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinations
Otto, C., Schwarz, T., Jeworowski, L. M., Schmidt, M. L., Walper, F., Pache, F., Schindler, P., Niederschweiberer, M., Krumbholz, A., Rose, R., Drosten, C., Ruprecht, K., Corman, V. M.
10.1101/2022.08.10.22278639 — Posted: 2022-08-11
Excess mortality in Cyprus during the COVID-19 pandemic and its lack of association with vaccination rates
Lytras, T., Athanasiadou, M., Demetriou, A., Stylianou, D., Heraclides, A., Kalakouta, O.
10.1101/2022.08.05.22278487 — Posted: 2022-08-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).